PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer

被引：0
|
作者：
Price, T. [1 ,2 ,3 ,4 ]
Rico, G. Tapia [1 ]
Williams, J. [1 ]
Yeend, S. [1 ]
Lo, L. [1 ]
Patel, D. [1 ,2 ]
Tebbutt, N. [4 ,5 ]
Shapiro, J. [4 ,6 ]
Burge, M. [4 ,7 ]
Gebski, V. [3 ]
Townsend, A. [1 ,2 ,4 ]
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Univ Adelaide, Adelaide, SA, Australia
[3] NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW, Australia
[4] AGITG, Sydney, NSW, Australia
[5] Austin Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Royal Brisbane Hosp, Brisbane, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
ORAL CHEMOTHERAPEUTIC-AGENT; XENOGRAFTS; EFFICACY; TAS-102;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [41] The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
    Michael Z. Liao
    Hans Prenen
    Sandeep Dutta
    Vijay V. Upreti
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 665 - 672
  • [42] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Naoki Nagata
    Hiromichi Maeda
    Keiichiro Ishibashi
    Keiji Hirata
    Akitaka Makiyama
    Shigeyoshi Iwamoto
    Hiroyoshi Takemoto
    Mitsunobu Imasato
    Yoichiro Yoshida
    Yoshinori Munemoto
    Chihiro Tanaka
    Yoshitaka Morita
    Yoshihiro Hotta
    Atsushi Toyofuku
    Takeshi Nagasaka
    Satoshi Morita
    Junichi Sakamoto
    Hideyuki Mishima
    Medical Oncology, 2019, 36
  • [43] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Nagata, Naoki
    Maeda, Hiromichi
    Ishibashi, Keiichiro
    Hirata, Keiji
    Makiyama, Akitaka
    Iwamoto, Shigeyoshi
    Takemoto, Hiroyoshi
    Imasato, Mitsunobu
    Yoshida, Yoichiro
    Munemoto, Yoshinori
    Tanaka, Chihiro
    Morita, Yoshitaka
    Hotta, Yoshihiro
    Toyofuku, Atsushi
    Nagasaka, Takeshi
    Morita, Satoshi
    Sakamoto, Junichi
    Mishima, Hideyuki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [44] The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
    Battaglin, Francesca
    Puccini, Alberto
    Djaballah, Selma Ahcene
    Lenz, Heinz-Josef
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5911 - 5924
  • [45] The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
    Liao, Michael Z.
    Prenen, Hans
    Dutta, Sandeep
    Upreti, Vijay V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (04) : 665 - 672
  • [46] Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer A Phase 2 Randomized Clinical Trial
    Napolitano, Stefania
    De Falco, Vincenzo
    Martini, Giulia
    Ciardiello, Davide
    Martinelli, Erika
    Della Corte, Carminia Maria
    Esposito, Lucia
    Famiglietti, Vincenzo
    Di Liello, Alessandra
    Avallone, Antonio
    Cardone, Claudia
    De Stefano, Alfonso
    Montesarchio, Vincenzo
    Zampino, Maria Giulia
    Bordonaro, Roberto
    Scartozzi, Mario
    Santini, Daniele
    Di Maio, Massimo
    De Vita, Ferdinando
    Altucci, Lucia
    Marrone, Francesca
    Ciardiello, Fortunato
    Troiani, Teresa
    JAMA ONCOLOGY, 2023, 9 (07) : 966 - 970
  • [47] First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
    Terazawa, Tetsuji
    Kato, Takeshi
    Goto, Masahiro
    Sakai, Daisuke
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Matsubara, Yoshihiro
    Satoh, Taroh
    BMC CANCER, 2019, 19 (1)
  • [48] Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
    Fumet, Jean-David
    Roussot, Nicolas
    Bertaut, Aurelie
    Limagne, Emeric
    Thibaudin, Marion
    Hervieu, Alice
    Zanetta, Sylvie
    Borg, Christophe
    Senellart, Helene
    Pernot, Simon
    Thuillier, Frederic
    Carnot, Aurelien
    Mineur, Laurent
    Chibaudel, Benoist
    Touchefeu, Yann
    Martin-Babau, Jerome
    Jary, Marine
    Labourey, Jean-Luc
    Rederstorff, Emilie
    Lepage, Come
    Ghiringhelli, Francois
    FUTURE ONCOLOGY, 2024, 20 (38) : 3077 - 3085
  • [49] First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
    Tetsuji Terazawa
    Takeshi Kato
    Masahiro Goto
    Daisuke Sakai
    Yukinori Kurokawa
    Toshio Shimokawa
    Yoshihiro Matsubara
    Taroh Satoh
    BMC Cancer, 19
  • [50] Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study
    Quan, Ming
    Chen, Jingde
    Chen, Zhiqin
    Hai, Yannan
    Zhou, Ying
    Chao, Qian
    Chen, Chen
    Li, Huajun
    Wang, Mei
    Gao, Yong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (11) : 1877 - 1884
12345